Bionovo's Estrogen Receptor Beta Selective Drugs Have Unique Gene Expression and Cell Type Specificity
EMERYVILLE, Calif., July 17 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI ) announced today that a study of the gene regulation in multiple cell lines by several of their estrogen receptor beta (ERb) candidates will be published in Public Library of Science One.
Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions
NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs
were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...
Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today that the FDA's Anti-Infective Drugs
Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with m...
Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study
- 12-week study concludes that new cosmeceutical improves skin barrier function, erythema and lesions associated with rosacea -
NAPA, Calif., May 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a life sciences company engaged in the development of technologies that targ...
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
NEW HAVEN, Conn., April 2 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced that its lead compound, delafloxacin, ha...
New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation
DALLAS, March 5 /PRNewswire/ -- A study published by Deborah S. Sarnoff, M.D. et al in the February issue of the Journal of Drugs
in Dermatology explores the new generation of carbon dioxide (CO2) laser skin resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes a...
Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer's Disease
Research Uncovers New Link Between Inflammation & Alzheimer's Disease
SARASOTA, Fla., Dec. 16 /PRNewswire/ -- The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer's disease and have identified a potential target for de...
Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome
REINACH, Switzerland, November 20 /PRNewswire-FirstCall/ -- Arpida (SWX:
ARPN) announced today that the Anti-infective Drugs
Advisory Committee of the
U.S. Food and Drug Administration (FDA) has voted 17 to 2 against the
approval of intravenous iclaprim, an antibiotic currently in development ...
Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
Study results to be presented at 2008 ICAAC/IDSA Joint Meeting
ROCKVILLE, Md., Oct. 28 /PRNewswire/ -- Sequella, Inc., a
clinical-stage biopharmaceutical company focused on commercializing
products to treat infectious diseases of epidemic potential, announces the
successful demonstration of ...
Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda
Oncology Company today announced new data from early non-clinical studies
of Millennium/Takeda-discovered pipeline molecules highlighting novel
therapeutic pathways in oncology. MLN4924 data build on the growing body of
VAI Finding Could Lead to New Drugs for Anxiety, Depression
Researchers determine molecular structure of promising drug target using new method
GRAND RAPIDS, Mich., Oct. 15 /PRNewswire/ -- Researchers in the
Laboratory of Structural Sciences at Van Andel Institute (VAI) have
determined how the hormone corticotrophin releas...
China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
HARBIN, China, Sept. 10 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (Amex: CSY ), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), announced today that it
Addrenex Pharmaceuticals' New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
DURHAM, N.C., Aug. 19 /PRNewswire/ -- Addrenex Pharmaceuticals (
http://www.addrenex.com ) has made three strategic hires this month to
further its goal of identifying and developing as many new drug candidates
as possible over the next 18 months.
The fast-paced timeline they have set for ...
Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
Owing to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources
WALTHAM, Mass., July 15 /PRNewswire/ -- Decision Resources, one of the
world's leading research and advisory firms focusing on pharmaceutical and
Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
Lead Candidate Set for Phase II Clinicals
LA JOLLA, Calif., June 11 /PRNewswire-FirstCall/ -- Duska Therapeutics,
Inc. (OTC Bulletin Board: DSKA) ("Duska" or the "Company"), announced today
that it has been granted an exclusive, worldwide license from Duke
University and Johns H...
Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
NEW YORK, April 8, 2008 /PRNewswire/ -- If you're suffering from back
pain and unable to find relief, it may be because the real cause of your
pain -- weak, stressed and damaged muscles, not your spine -- has never
been recognized or treated, says Norman Marcus, M.D., one of the nation's
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the Clinical Gold Standard Through 2016, According to a New Report from Decision Resources
WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one
of the world's leading research and adv...
Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
GAITHERSBURG, Md., March 13 /PRNewswire/ -- Ortho Biotech is concerned
by the Advisory Committee's recommendations to restrict access to
erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia
(CIA) in patients with metastatic breast and head and neck cancer, and
NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
NEW YORK, Feb. 22 /PRNewswire/ -- NexGenix Pharmaceuticals, presented
data on its Hsp90 inhibitor program today at the GTCBio 5th Annual Cancer
Drugs Research & Development Conference taking place in Phoenix, Arizona.
The company presented data on NXD30001, one of several novel,
Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
BETHESDA, Md., Feb. 12 /PRNewswire-FirstCall/ -- Micromet, Inc.
(Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary
antibodies for the treatment of cancer, inflammation and autoimmune
diseases, today announced the publication of a comprehensive review article
Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
AVALIDE demonstrated powerful mean blood pressure reductions of 30.8 mm Hg
systolic blood pressure (SBP) and 24.0 mm Hg diastolic blood pressure (DBP)
at five weeks and 21.1/19.3 mm Hg (SBP/DBP) for irbesartan alone in a study of patients with severe hypertension
AVALIDE also de...
Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
BOSTON, Oct. 5 /PRNewswire/ -- Surface Logix, Inc. today announced the
presentation of positive safety and efficacy data from its innovative Phase
1 repeat-dose clinical trial of its investigational drug candidate
SLx-4090, a first-in-class enterocyte-specific microsomal triglyceride
Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Lead Compound Produces Significant LDL-Cholesterol Reduction and Weight Loss When Combined with Zetia(R) in Hypercholesterolemic Patients
BRIDGEWATER, N.J., Oct. 4 /PRNewswire/ -- Aegerion Pharmaceuticals,
Inc., a specialty pharmaceutical company focused on the treatment of
Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
LAKE FOREST, Calif., Sept. 18 /PRNewswire/ -- Worldwide markets of
approved EGFr/HEr2 inhibitors grew by 34.2% during the first half of 2007,
pushing sales to more than $3.2 billion, exceeding total sales reported in
2005. Hundreds of clinical trials are ongoing, aimed at expanding
Dry Mouth Linked to Prescription and Over the Counter Drugs
BALTIMORE, July 9 /PRNewswire-USNewswire/ -- Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD). Dry mouth, or xerostomia , is caused by...
Key Protein May Lead to Faster Acting Anti-Depression Drugs
NEW YORK, March 23 /PRNewswire-USNewswire/ -- Research conducted by Nobel laureate Paul Greengard, Medical Director of The Michael Stern Parkinson's Research Center at The Rockefeller University , Dr. Jennifer L. Warner-Schmidt in New York and colleagues in Sweden, demonstrated in the Journal o...
The Children's Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohn's Disease Drugs
- Broadens Power of Current Genetic Discovery Techniques -
PHILADELPHIA, Feb. 26 /PRNewswire-USNewswire/ -- Discovering the different genes that contribute to a complex disease is like searching in the proverbial haystack for an unknown number of needles -- some much smaller than others, ...
Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs
Study results pending publication in July print edition of Clinical Chemistry, available on Web
INDIANAPOLIS, July 23 /PRNewswire/ -- A Roche Diagnostics-sponsored
pilot study evaluating the use of N-terminal pro-B-type natriuretic peptide
(NT-proBNP) confirms the potent...
Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
- Results Presented at Endocrine Society's 90th Annual Meeting -
SAN FRANCISCO and EMERYVILLE, Calif., June 16 /PRNewswire-FirstCall/ --
Bionovo Inc. (Nasdaq: BNVI ) today announced results on the role of estrogen
regulatory elements important in developing drugs
for breast cancer and
Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
ARLINGTON, Va., May 6 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the
development of advanced preclinical platforms and tumor specific data to
enhance the value of oncology drugs, announced today the completion of a
First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
HWI Scientist Dr. Dan Gewirth's Groundbreaking Research Makes Cover of Molecular Cell
BUFFALO, N.Y., Oct. 19 /PRNewswire/ -- Dr. Dan Gewirth,
Hauptman-Woodward senior research scientist, has just solved the structure
of the first mammalian GRP94 protein implicated ...
Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
- Publication in Leading Peer-Reviewed Journal Represents Further
Scientific Validation of the Potential Utility of Modigene's CTP Technology -
VIENNA, Va., Sept. 24 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC
Bulletin Board: MODG) today reported that rese...
New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
MELBOURNE, Australia, Aug. 28 /PRNewswire/ -- Cancer Therapeutics CRC
Pty Ltd (CTx) has commenced operations as one of the largest public/private
partnerships of its type in the world. Underpinned by AUD$148 million in funding over seven years, including
AUD$37.6 million from the Australian C...
Research Supported by Samuel Waxman Cancer Research Foundation
Discovers Mode of Action of Arsenic-Based Drugs in Destroying
NEW YORK--(BUSINESS WIRE)--Apr 16, 2007 - Arsenic, a naturally
occurring element, has been used in therapeutic compounds for over
2,000 years, and even now remains a venerable constituent of the
traditional Chinese pharmacopeia.
Today, due in measure to the efforts of investigators supported
NanoViricides Drugs Found To Be Highly Effective Against Most
Recent Strain of the H5N1 Avian Flu Virus
WEST HAVEN, Conn.--(BUSINESS WIRE)--May 7, 2007 - NanoViricides,
Inc. (Pink Sheets: NNVC) presented results of recent animal studies
against rabies and BSL3 in vitro studies against a Clade 2 H5N1
(avian influenza) virus at the 23rd Annual Symposium of the Pan
American Society for Clinical Virology...
Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
NEW YORK, June 13, 2007--Three new drugs
rheumatoid arthritis (RA) have ushered in a new era of treatment
for this difficult and debilitating condition. The findings are
reported in a New Drug Class study published early Online and in an
upcoming edition of The Lancet.
RA is the most common ...
New Report 'Looking at Chiral Technologies' Analyzes the Global
Market Growth Forecasts Driven By Two Very Important Components as
Single Isomer Drugs and Single Enantiomer Pharmaceuticals
DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and
Markets (http://www.researchandmarkets.com/reports/c60415) has
announced the addition of Looking at Chiral Technologies to their
The advancements in molecular research and continued untiring
efforts of the research industry to...
New Drugs in Multinational Study Show Promise in Fighting
Phase III clinical trial provides hope that HIV patients can live
PASADENA, Calif., July 05, 2007 /PRNewswire/ -- A new
investigational drug used in combination with a second newer agent
has proven to be effective in fighting drug-resistant HIV,
according to a Lancet article to be pub...
Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
In keeping with the recent proliferation of rapid, easy-to-use diagnostic tests, many assays and collection products have entered the marketplace to help clinicians assess dosage appropriateness of therapeutic drugs
and to screen for the presence of drugs
of abuse. Some of these products require l...
Global Rabies Treatment May be Possible with NanoViricides Drugs
WEST HAVEN, Conn.--(BUSINESS WIRE)--May 14, 2007 - NanoViricides,
Inc. (Pink Sheets: NNVC) discussed today the results of recent
animal studies against rabies that were presented along with the
successful BSL3 in vitro studies against a Clade 2 H5N1 virus at
the 23rd Annual Symposium of the Pan Ame...